Top 10 Small Cap Companies For 2015

Top 10 Small Cap Companies For 2015: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Ben Levisohn]

  Bottom line from the Gilead standpoint for us is theJohnson & Johnson for Alios transaction is particularly interesting for 1) its RSV candidate to watch, 2) longer-term Alios has two nukes going into the clinic. 3) whether this has any read-through into companies that still might be interested in Achillion’s (ACHN) Phase I nuke program which will have data this fall and investors expect that to be acquired too since there were multiple bidders for Idenix Pharmaceuticals (IDIX). 4) This may also suggest ifJohnson & Johnson continues development of these nukes that there is still a long tail for HCV if they want to invest in this for a drug that would be on the market out in 2018.

• [By Roberto Pedone]

  An under-$10 biotechnology player that's sta! rting to trend within range of triggering a big breakout trade is Achillion Pharmaceuticals (ACHN), discovers, develops and commercializes anti-infective drug therapies in the U.S. and internationally. This stock has been destroyed by the sellers so far in 2013, with shares down big by 66%.

  If you take a look at the chart for Achillion Pharmaceuticals, you'll notice that this stock has been trending sideways for the last month and change, with shares moving between $2.26 on the downside and $2.98 on the upside. This sideways trading pattern is occurring after shares of ACHN gapped down sharply in late September from $7.50 to under $3 with heavy downside volume. Shares of ACHN are now starting to trend higher and move within range of triggering a big breakout trade above the upper-end of its sideways trading chart pattern.

  Traders should now look for long-biased trades in ACHN if it manages to break out above some near-term overhead resistance levels at $2.85 to $2.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.76 million shares. If that breakout triggers soon, then ACHN will set up to re-test or possibly take out its gap down day high from September at $3.62 a share. Any high-volume move above that level will then give ACHN a chance to re-fill some of its previous gap down zone that started at $7.50 a share.

  Traders can look to buy ACHN off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.44 to $2.26 a share. One can also buy ACHN off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-10-small-cap-companies-for-2015-2.html